CA3140716A1 - Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer - Google Patents

Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer Download PDF

Info

Publication number
CA3140716A1
CA3140716A1 CA3140716A CA3140716A CA3140716A1 CA 3140716 A1 CA3140716 A1 CA 3140716A1 CA 3140716 A CA3140716 A CA 3140716A CA 3140716 A CA3140716 A CA 3140716A CA 3140716 A1 CA3140716 A1 CA 3140716A1
Authority
CA
Canada
Prior art keywords
substituted
compound
a1ky1
a1koxy
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3140716A
Other languages
English (en)
French (fr)
Inventor
Jonathan L. Sessler
Sajal SEN
Jonathan F. ARAMBULA
Zhengrong Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA3140716A1 publication Critical patent/CA3140716A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/12—Gold compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/10—Silver compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3140716A 2019-05-22 2020-05-22 Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer Pending CA3140716A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851187P 2019-05-22 2019-05-22
US62/851,187 2019-05-22
PCT/US2020/034415 WO2020237225A1 (en) 2019-05-22 2020-05-22 Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
CA3140716A1 true CA3140716A1 (en) 2020-11-26

Family

ID=73459479

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3140716A Pending CA3140716A1 (en) 2019-05-22 2020-05-22 Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer

Country Status (11)

Country Link
US (1) US12577262B2 (https=)
EP (1) EP3972981A4 (https=)
JP (1) JP2022532801A (https=)
KR (1) KR20220024123A (https=)
CN (1) CN114174305A (https=)
AU (1) AU2020279478A1 (https=)
CA (1) CA3140716A1 (https=)
IL (1) IL288176A (https=)
MX (1) MX2021014195A (https=)
SG (1) SG11202112856QA (https=)
WO (1) WO2020237225A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201003483D0 (en) * 2010-03-02 2010-04-14 Univ St Andrews Gold complexes
US8900654B2 (en) * 2011-07-29 2014-12-02 Thin Film Electronics, Inc. Methods of polymerizing silanes and cyclosilanes using N-heterocyclic carbenes, metal complexes having N-heterocyclic carbene ligands, and lanthanide compounds
HUE033704T2 (en) 2012-02-13 2017-12-28 Bristol Myers Squibb Co Enediyne compounds, conjugates thereof, and uses and methods therefor
US20170129911A1 (en) 2015-11-10 2017-05-11 Massachusetts Institute Of Technology Complexes comprising a platinum compound and an immune checkpoint inhibitor and related methods
WO2019006327A1 (en) * 2017-06-30 2019-01-03 Board Of Regents, The University Of Texas System OR-CARBENE COMPLEXES CONTAINING NAPHTOQUINONE AND METHODS OF USE

Also Published As

Publication number Publication date
EP3972981A4 (en) 2023-05-24
KR20220024123A (ko) 2022-03-03
EP3972981A1 (en) 2022-03-30
US12577262B2 (en) 2026-03-17
AU2020279478A1 (en) 2021-12-09
CN114174305A (zh) 2022-03-11
WO2020237225A1 (en) 2020-11-26
IL288176A (en) 2022-01-01
JP2022532801A (ja) 2022-07-19
MX2021014195A (es) 2022-02-21
SG11202112856QA (en) 2021-12-30
US20220340601A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
US12472187B2 (en) Texaphyrin-Pt(IV) conjugates and compositions for use in overcoming platinum resistance
WO2015070766A1 (zh) 一种n-苄基色胺酮衍生物及其制备方法和应用
US20230303503A1 (en) Cell activatable iron chelators
CN104163823B (zh) 一种喜树碱与青蒿琥酯偶联物及其制备方法与应用
NO324594B1 (no) Nye indolderivater, fremgangsmate for fremstilling derav og deres anvendelse og medikamenter inneholdende derivatene.
CN105566305B (zh) 4-(取代苯胺基)喹唑啉衍生物二甲苯磺酸盐的多晶型物及其制备方法和用途
US12577262B2 (en) Functionalized gold carbene napthaquinone complexes for use in the treatment of cancer
CN118320117B (zh) 多细胞器靶向、原位释放的分子基药物递送系统
CN103804388B (zh) 4β-氮取代呋喃叔胺类鬼臼毒素衍生物及其制备方法与应用
US20260053931A1 (en) Mdm2 targeting protacs
TW202039457A (zh) 一類含氟取代的苯并噻吩類化合物及其藥物組合物及應用
CN114874245A (zh) 一种二硫代氨基甲酸金属配合物的前药化合物及其制备方法与应用
CN110183471B (zh) 一种哌嗪类衍生物及制备方法及应用
CN120098064A (zh) 一种src-3 protac化合物及其制备方法和在治疗乳腺癌中的应用
CN103951716B (zh) 豆腐果苷衍生物及其制备方法和用途
CN111170996A (zh) 具有alk抑制活性的嘧啶衍生物及其合成方法和应用
HK1236416A1 (zh) 用於克服铂耐受性的德克萨卟啉-pt(iv)缀合物及组合物
WO2010051664A1 (zh) 7H-咪唑并[1,2-a]吡喃并[2,3-c]吡啶类衍生物及其应用

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240703

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20241122

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20251124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260105